Last reviewed · How we verify
NCT05211960
Effects of a Mindfulness App for Outpatients Waitlisted for Psychological Interventions
NA trial testing Mindfulness-based meditation in Mental Disorder in 193 participants. Completed in 30 April 2024.
30 April 2024
Quick facts
| Lead sponsor | Centre for Addiction and Mental Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 193 |
| Start date | 24 January 2022 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 April 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Mindfulness-based meditation
Conditions studied
- Mental Disorder — all drugs for Mental Disorder →
Sponsor
Centre for Addiction and Mental Health — full company profile →
Who can join
Adults 18 to 65, any sex, with Mental Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate a mindfulness-based meditation app provided to outpatients (or community participants) who are waitlisted for standard psychological care for mental health or substance use concerns.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Acceptability, engagement, outcomes, and dose-response associations of a mindfulness-based meditation app in individuals waiting for psychological services
Daros AR, Patel A, Otevwe O, Sotelo S, et al · · 2024 · DOI 10.21203/rs.3.rs-4952898/v1
Verify or expand the search:
- PubMed search for NCT05211960
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mental Disorder
Currently open trials in the same condition.
- NCT07010614 — Brain Stimulation to the Hippocampus in Schizophrenia · NA · recruiting
- NCT06929533 — Pharmacogenomics-Supported Psychotropic Prescribing Trial · NA · recruiting
- NCT06813066 — Simulating Psychotherapeutic Sessions With Generative Artificial Intelligence · NA · active not recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT06625437 — ACT for HIV-Positive Men · NA · recruiting
Other Centre for Addiction and Mental Health trials
Trials by the same sponsor.
- NCT07211438 — Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression · Phase 2 · not yet recruiting
- NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting
- NCT07228923 — Development and Evaluation of a Theory and Evidence-based Intervention to Reduce Hazardous Alcohol Consumption Among Tre · NA · not yet recruiting
- NCT07105449 — THC Titration of High-Potency Cannabis Concentrates · NA · not yet recruiting
- NCT06928935 — Digital Dialectical Behavioural Therapy (d-DBT) for Youth at Clinical High Risk (CHR) for Psychosis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05211960 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Addiction and Mental Health
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05211960.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing